ClinicalTrials.gg
Not yet recruitingNCT06572761ECHEC-MATUpdated May 1, 2026

A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor

A Phase 3 interventional study of Combination of antibiotics and Emergency cerclage in Previable Labour With Intact Membranes, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, 2 of them phase 3. Premature Birth · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
9th of 20
350 · median 133
Started
2026
with 1 other
Phase 3
4 of 26
1 open now
Registered
24th of 26
by date

Among the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, this one is the 9th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 3, and was the 24th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

6 of the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether a combination of antibiotics (cephalosporin 3rd generation, clarithromycin, metronidazole) are effective to prolong pregnancies complicated with previable threatened labour with intact membranes.

Read the detailed description

Observational data suggest that subclinical infectious conditions can lead to spontaneous preterm labor. 10% of births are premature, but the morbidity/mortality of premature babies is concentrated mainly among newborns born before 30 weeks of gestation or weighing less than 1500 g. The relationship to infection/inflammation and premature birth is not constant throughout pregnancy, but this infectious risk increases the earlier the gestational age of spontaneous labor is (before 30 weeks). The pathogens that have the strongest associations with premature birth are Gardnerella vaginalis, Ureaplasma urealyticum and Mycoplasma hominis, but also Streptococcus B, Escherichia coli, Klebsiella spp, or Haemophilus influenzae.

Antibiotic treatment to treat an intra-amniotic infection is considered ineffective. Indeed, the last randomized trial (Oracle 2, 2001), which studied several antibiotic regimens for threatened premature delivery with intact membranes, did not find a significant reduction in neonatal morbidity/mortality after administration of co-beta-lactam, erythromycin or the combination of both. In addition, this large trial dominates the results of the latest Cochrane meta-analysis which evaluated preventive antibiotic therapy to stop premature labor with intact membranes.

Recently, it has been showed that a new combination of antibiotics (ceftriaxone, clarithromycin and metronidazole) reduced the risk of infection and intra-amniotic inflammation in preterm labor with intact membranes. This retrospective study deserves to be confirmed by a randomized study

The investigator's goal is to study whether a new combination of antibiotics in a very limited population of pregnancies complicated by the threat of late miscarriage would make it possible to prolong pregnancies in order to improve neonatal outcomes.

03

Conditions studied

  • Previable Labour With Intact Membranes

Browse trials for

Keywords

  • previable labour
  • preterm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Threatened previable prelabor with intact membranes between 18weeks of gestation +0/7 and 23 weeks of gestation 6/7 SA defined on endovaginal ultrasound by a short cervix ≤10 mm, and/or protrusion of the membranes on speculum examination.
  • Maternal age >18 years
  • Affiliated with social security
  • Correct understanding of the French language
  • Singleton pregnancy
  • Foetus alive at time of inclusion
  • Absence of regular and painful uterine contractions

Exclusion criteria

Exclusion Criteria:

  • Premature labor defined by regular, painful uterine contractions and a short cervix
  • Protected person (patient under guardianship/curatorship/or legal protection)
  • Multiple pregnancies
  • Premature rupture of membranes
  • Acute chorioamnionitis
  • to protocol antibiotics
  • Chromosomal abnormality, congenital malformation
  • Patients who received antibiotics before randomization, or requiring antibiotics for another indication (chorioamnionitis, pyelonephritis, etc.)
  • Participation in another research (Specify the category: RIPH, EC, IC, etc.) or being in the exclusion period following previous research involving humans, if applicable
  • Patient under AME (if no exemption from affiliation)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    Combination of antibiotics

    Combination of antibiotics (3rd generation of cephalosporin, clarithromycin, metronidazole) \+ routine care (emergency cerclage, vaginal progesterone)

    Drug: Combination of antibiotics · Device: Emergency cerclage · Drug: Vaginal progesterone

  • Active comparator
    Routine care

    Routine care (emergency cerclage, vaginal progesterone)

    Device: Emergency cerclage · Drug: Vaginal progesterone

Interventions

  • DrugCombination of antibiotics

    Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally

    Also known as: Ceftriaxone; clarithromycin, metronidazole

  • DeviceEmergency cerclage

    Emergency cerclage

  • DrugProgesteroneStudies of ProgesteroneProgesterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vaginal progesterone

06

What researchers measure

Primary outcomes

  1. A perinatal composite outcome

    * Late miscarriage * Perinatal mortality * Bronchodysplasia, * Sepsis proven by blood culture, * Intraventricular hemorrhage ≥3, * Periventricular leukomalacia ≥2, * Ulcero-necrotizing enterocolitis at stage ≥2 according to the Bell classification.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Gestationnal age at delivery

    * Gestationnal age at delivery ≥ 24 weeks of gestation (wg) 0/7, 28 wg0/7, 32 wg0/7, 34 wg0/7 et 37 wg0/7 * Latency period between randomisation and delivery (≥2 days, ≥7 days, ≥14 days et ≥28 days)

    Time frame: 6 months

  2. Maternal Morbidty

    Chorioamniotitis, postpartum endometritis , sepsis proven par positive hemocultures

    Time frame: 6 months

  3. Bacteriological

    Acquisition of multi-resistant germs during childbirth

    Time frame: 6 months

07

Study locations

1 site
  • Centre Hospitalier Poissy-Saint Germain
    Poissy, 78300, France
    • Thibaud QUIBEL, MD, PhD · Contact0178636012
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for May 2030, 44 months later.

Of 35 non-industry phase 3 interventional studies under Premature Birth, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 89. This study's planned 44 months is below that.

Counting every sponsor, half of 40 studies reached it within 51 months; a quarter within 28 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2024
First posted
Aug 27, 2024
StartEst.
Sep 2026
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06572761
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Sep 2026 (estimated)
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
May 1, 2026

Study contacts

Thibaud QUIBEL, MD, PhD
Contact
thibaud.quibel@ght-yvelinesnord.fr
0178636012
Charly LARRIEU
Contact
charly.larrieu@aphp.fr
01 58 41 34 78
Thibaud QUIBEL, MD, PhD
principal investigator · Centre Hospitalier Poissy-Saint Germain
Jean BOUYER
study chair · Institut National de la Santé Et de la Recherche Médicale, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion